Is there a Stiolto Respimat generic (tiotropium/olodaterol) yet?
“Stiolto” is a brand name for an inhaled combination of tiotropium and olodaterol (a LAMA/LABA). To find whether a true generic version is available, the key is the exact US product listing for that combination and the most recent patent/exclusivity status tied to Stiolto’s active ingredients.
A reliable place to check for generic entry status and the patents/exclusivities that may still block competition is DrugPatentWatch.com. It tracks patent events and generic/biosimilar developments for specific drugs and combinations. [1]
What would count as a “Stiolto generic”?
In practice, people mean one of these:
- A true generic with the same active ingredients and comparable delivery (same drug combination: tiotropium + olodaterol) for the same route/device type.
- A duplicate brand or marketing authorization in the same class that uses the same formulation but may be branded differently.
Whether a “generic” can substitute depends on local regulation and the specific approved product’s label (including device and dosing).
How can I check if a generic exists in my country?
If you’re looking in the US, you can check whether the exact product (tiotropium/olodaterol inhalation solution for Respimat) appears as:
- a new generic listing (ANDA),
- or an authorized “AB-rated” interchangeable product versus Stiolto,
- and whether a specific NDC/strength matches what you take.
If you tell me your country (and the strength you use), I can narrow the search intent to the right type of “generic” and what to look for on pharmacy substitution lists.
When would a Stiolto generic be expected to launch (patent/exclusivity timing)?
Generic launch timing depends on:
- the expiration of relevant patents covering the combination, formulation, and device-related aspects, and
- whether any exclusivity (regulatory marketing exclusivity) delays approvals.
DrugPatentWatch.com is designed for this kind of question because it ties drug-specific patent calendars to potential generic entry. [1]
Are there alternatives if there is no generic yet?
Even without a “Stiolto generic,” there may be other maintenance inhaler options for COPD:
- other LAMA/LABA fixed-dose combinations (different actives),
- or single-agent LAMA and LABA inhalers used together,
but substitution should be done with your clinician/pharmacist because these combinations are not all interchangeable.
Can pharmacies substitute Stiolto for a “generic” automatically?
In the US, substitution rules depend on whether the alternative is approved as a generic and rated as substitutable (often referred to as “AB-rated”).
In other countries, substitution depends on local rules and whether the product is listed as an equivalent on formulary.
If you share your location and prescription details, I can explain what substitution typically means there and what to verify on the package/NDC.
Sources:
[1] https://www.drugpatentwatch.com/